ARTICLE | Clinical News
FDA approves Aclaris' Eskata to treat SK
December 22, 2017 7:53 PM UTC
Aclaris Therapeutics Inc. (NASDAQ:ACRS) said FDA approved Eskata hydrogen peroxide topical solution 40% to treat raised seborrheic keratosis (SK).
Aclaris plans to launch Eskata in the U.S. in spring 2018. It will be available as a self-pay aesthetic treatment. ...
BCIQ Company Profiles